Diagnostics
This study will evaluate Abecma in patients with suboptimal response to transplant Data from KarMMa-3 and KarMMa-2 studies of Abecma will be presented at future medical meeting Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–2seventy bio, Inc. (Nasdaq: TSVT) today announced plans to initiate the KarMMa-9 study to evaluate Abecma (idecabtagene vicleucel) in newly diagnosed…
Read MoreDiagnostics enable the detection of the monkeypox virus in humans Excerpt from the Press Release: SAN DIEGO, Aug. 18, 2022 /PRNewswire/ — CorDx, a global leader in the development, manufacturing, and distribution of diagnostics and medical devices, was recently granted a CE Mark certificate for two of the company’s monkeypox diagnostic tests. The CE Mark,…
Read MoreExcerpt from the Press Release: Valo’s Opal Computational Platform™ being used to select a patient subset within non-proliferative diabetic retinopathy patients at high risk of progressing toward vision-threatening disease BOSTON, Aug. 18, 2022 /PRNewswire/ — Valo Health, Inc. (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and…
Read MorePhase 2 trial showed that relacorilant plus nab-paclitaxel improved progression-free survival, duration of response and overall survival without an increased side effect burden compared to nab-paclitaxel alone Excerpt from the Press Release: MENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development…
Read MoreExcerpt from the Press Release: Alzheimer’s disease is the most common form of dementia, one of the major causes of dependency and disability in older adults. Though advances have been made in understanding the harrowing brain disease, diagnostic tests are currently limited and there are no treatments. Now, a uOttawa Faculty of Medicine assistant professor and a…
Read MoreExcerpt from the Press Release: SAN JOSE, Calif., May 24, 2022 /PRNewswire/ — OptraSCAN®, the leading end-to-end digital pathology solution provider, announced its digital pathology scanner OS-SiA has been granted US patent – No 2020/0334814 A1 by the United States Patent and Trademark Office. OS-SiA has inbuilt intelligence to scan, index and analyze pathological samples…
Read MoreAutomated and Easily Scalable Swab-Based Workflow Supports Increased Sample Throughput and Processing Consistency Excerpt from the Press Release: WALTHAM, Mass. & WATERTOWN, Mass.–(BUSINESS WIRE)–Rhinostics Inc. and Nexus Medical Labs recently received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a molecular SARS-CoV-2 test enabling unsupervised self-collection. The test, based on…
Read MoreAbstracts Highlight In Vitro and In Vivo Activity of Qualigen’s Pan-RAS inhibitor in (1) Pancreatic Cancer, and (2) Malignant Peripheral Nerve Sheath Tumors Excerpt from the Press Release: CARLSBAD, Calif., May 26, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers…
Read MoreOption agreement comprises three technologies and associated patent portfolios Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative cell therapy platforms Excerpt from the Press Release: WEXFORD, Pa., May 17, 2022 /PRNewswire/ — Coeptis Therapeutics, Inc. (OTC PINK: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing…
Read MoreExcerpt from the Press Release: The Ontario Brain Institute (OBI) has released a new set of clinical imaging modalities from a Province of Ontario Neurodevelopmental Network (POND) study for cohort of over 600 children and youth, some diagnosed with various neurodevelopmental disorders and others typically developing.This cleaned, standardized, and curated dataset is available for download on Brain-CODE, OBI’s neuroinformatics and analytics platform.…
Read More